Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:03:16.753Z.
Calculation as of: 2026-10-06T15:03:16.753Z.
Quote observation: 2026-10-06T15:00:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9f9faf5d94760910c623181769e7db2d3dbfaf2deb8efb054b569f6f0254c4bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Jaguar Health, Inc.
Market Cap
$2.68M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Jaguar Health, Inc. (JAGX) | $2.68M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.55M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.63M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.58M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.55M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.40M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $2.94M | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.25M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
